Calliditas: An approval in China during 2023 is now more likely - Redeye

Calliditas partner in China (including South Korea, Hong Kong, Macau, Taiwan and Singapore) Everest Medical has announced that the Center for Drug Evaluation in China has recommended a Priority Review for Nefecon.

Länk till analysen i sin helhet: https://www.redeye.se/research/870005/calliditas-an-approval-in-china-during-2023-is-now-more-likely?utm_source=finwire&utm_medium=RSS